secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-08-03T10:40:42+00:00
Accession:  0001193125-26-329513
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior to merge with Supernus in stock-for-stock deal; Indivior stockholders to own 56.5% of combined company
--------------------------------------------------------------------------------

- Exchange ratio: 1.5401 Indivior shares per Supernus share; Indivior stockholders own ~56.5%, Supernus ~43.5% on fully diluted basis.
- Indivior to pay $1B special dividend pre-closing, funded in part by $650M senior secured term loan from Citibank.
- Combined company renamed Supernus, Inc., trades on Nasdaq under 'SUPN'; Jack Khattar CEO, Timothy Dec CFO; board split 4-4.
- Termination fees: Indivior pays $174M if it walks for superior proposal; Supernus pays $101M; closing subject to stockholder and regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/0001193125-26-329513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/d28447d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-329513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer